Joshua R Willard1, Breanne M Barrow1, Sakeneh Zraika2,3. 1. Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way (151), Seattle, WA, 98108, USA. 2. Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way (151), Seattle, WA, 98108, USA. zraikas@uw.edu. 3. Division of Metabolism, Endocrinology & Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA. zraikas@uw.edu.
Abstract
AIM/HYPOTHESIS: Neprilysin, a widely expressed peptidase, is upregulated in metabolically altered states such as obesity and type 2 diabetes. Like dipeptidyl peptidase-4 (DPP-4), neprilysin can degrade and inactivate the insulinotropic peptide glucagon-like peptide-1 (GLP-1). Thus, we investigated whether neprilysin deficiency enhances active GLP-1 levels and improves glycaemia in a mouse model of high fat feeding. METHODS: Nep +/+ and Nep -/- mice were fed a 60% fat diet for 16 weeks, after which active GLP-1 and DPP-4 activity levels were measured, as were glucose, insulin and C-peptide levels during an OGTT. Insulin sensitivity was assessed using an insulin tolerance test. RESULTS: High-fat-fed Nep -/- mice exhibited elevated active GLP-1 levels (5.8 ± 1.1 vs 3.5 ± 0.8 pmol/l, p < 0.05) in association with improved glucose tolerance, insulin sensitivity and beta cell function compared with high-fat-fed Nep +/+ mice. In addition, plasma DPP-4 activity was lower in high-fat-fed Nep -/- mice (7.4 ± 1.0 vs 10.7 ± 1.3 nmol ml-1 min-1, p < 0.05). No difference in insulin:C-peptide ratio was observed between Nep -/- and Nep +/+ mice, suggesting that improved glycaemia does not result from changes in insulin clearance. CONCLUSIONS/ INTERPRETATION: Under conditions of increased dietary fat, an improved glycaemic status in neprilysin-deficient mice is associated with elevated active GLP-1 levels, reduced plasma DPP-4 activity and improved beta cell function. Thus, neprilysin inhibition may be a novel treatment strategy for type 2 diabetes.
AIM/HYPOTHESIS: Neprilysin, a widely expressed peptidase, is upregulated in metabolically altered states such as obesity and type 2 diabetes. Like dipeptidyl peptidase-4 (DPP-4), neprilysin can degrade and inactivate the insulinotropic peptide glucagon-like peptide-1 (GLP-1). Thus, we investigated whether neprilysin deficiency enhances active GLP-1 levels and improves glycaemia in a mouse model of high fat feeding. METHODS:Nep +/+ and Nep -/- mice were fed a 60% fat diet for 16 weeks, after which active GLP-1 and DPP-4 activity levels were measured, as were glucose, insulin and C-peptide levels during an OGTT. Insulin sensitivity was assessed using an insulin tolerance test. RESULTS: High-fat-fed Nep -/- mice exhibited elevated active GLP-1 levels (5.8 ± 1.1 vs 3.5 ± 0.8 pmol/l, p < 0.05) in association with improved glucose tolerance, insulin sensitivity and beta cell function compared with high-fat-fed Nep +/+ mice. In addition, plasma DPP-4 activity was lower in high-fat-fed Nep -/- mice (7.4 ± 1.0 vs 10.7 ± 1.3 nmol ml-1 min-1, p < 0.05). No difference in insulin:C-peptide ratio was observed between Nep -/- and Nep +/+ mice, suggesting that improved glycaemia does not result from changes in insulin clearance. CONCLUSIONS/ INTERPRETATION: Under conditions of increased dietary fat, an improved glycaemic status in neprilysin-deficient mice is associated with elevated active GLP-1 levels, reduced plasma DPP-4 activity and improved beta cell function. Thus, neprilysin inhibition may be a novel treatment strategy for type 2 diabetes.
Authors: Daniela Lamers; Susanne Famulla; Nina Wronkowitz; Sonja Hartwig; Stefan Lehr; D Margriet Ouwens; Kristin Eckardt; Jean M Kaufman; Mikael Ryden; Stefan Müller; Franz-Georg Hanisch; Johannes Ruige; Peter Arner; Henrike Sell; Juergen Eckel Journal: Diabetes Date: 2011-05-18 Impact factor: 9.461
Authors: Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst Journal: Diabetologia Date: 2017-07-01 Impact factor: 10.122
Authors: Jelena P Seferovic; Brian Claggett; Sara B Seidelmann; Ellen W Seely; Milton Packer; Michael R Zile; Jean L Rouleau; Karl Swedberg; Martin Lefkowitz; Victor C Shi; Akshay S Desai; John J V McMurray; Scott D Solomon Journal: Lancet Diabetes Endocrinol Date: 2017-03-18 Impact factor: 32.069
Authors: Nathalie Esser; Stephen M Mongovin; Jacqueline Parilla; Breanne M Barrow; Thomas O Mundinger; Brendy S Fountaine; Megan J Larmore; Joseph J Castillo; Rehana Akter; Rebecca L Hull; Sakeneh Zraika Journal: Am J Physiol Endocrinol Metab Date: 2022-02-07 Impact factor: 4.310
Authors: Nathalie Esser; Christine Schmidt; Breanne M Barrow; Laura Cronic; Daryl J Hackney; Stephen M Mongovin; Meghan F Hogan; Andrew T Templin; Joseph J Castillo; Rebecca L Hull; Sakeneh Zraika Journal: Front Endocrinol (Lausanne) Date: 2022-06-06 Impact factor: 6.055
Authors: Christoph Maack; Michael Lehrke; Johannes Backs; Frank R Heinzel; Jean-Sebastien Hulot; Nikolaus Marx; Walter J Paulus; Patrick Rossignol; Heinrich Taegtmeyer; Johann Bauersachs; Antoni Bayes-Genis; Dirk Brutsaert; Heiko Bugger; Kieran Clarke; Francesco Cosentino; Gilles De Keulenaer; Alessandra Dei Cas; Arantxa González; Martin Huelsmann; Guido Iaccarino; Ida Gjervold Lunde; Alexander R Lyon; Piero Pollesello; Graham Rena; Niels P Riksen; Giuseppe Rosano; Bart Staels; Linda W van Laake; Christoph Wanner; Dimitrios Farmakis; Gerasimos Filippatos; Frank Ruschitzka; Petar Seferovic; Rudolf A de Boer; Stephane Heymans Journal: Eur Heart J Date: 2018-12-21 Impact factor: 29.983